ArticleCancer cell2010
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
Article in Cancer cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 141 citations in OpenAlex.
- HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025Review
- Article
- The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.Breast cancer research and treatment · 2024Article
- Resistance to Trastuzumab.Cancers · 2022Review
- Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.Cancer research · 2022Article
- Pan-Cancer Analysis Based onFrontiers in oncology · 2022Article
- Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition.Cell communication and signaling : CCS · 2021Review
- Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN.Cell death & disease · 2021Article
- Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.Molecular cancer research : MCR · 2021Article
- Erythropoietin and its derivatives: from tissue protection to immune regulation.Cell death & disease · 2020Review
- Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.Breast cancer research : BCR · 2019Article
- Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.Translational oncology · 2019Article
- Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells.Cell death & disease · 2019Article
- Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy.Biologics : targets & therapy · 2019Review
- P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim.Nature communications · 2018Article
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.Cancer letters · 2018Article
- De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Breast (Edinburgh, Scotland) · 2017Review
- Erythropoietin drives breast cancer progression by activation of its receptor EPOR.Oncotarget · 2017Article
- Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.Journal of cancer stem cell research · 2017Article
- New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.Frontiers in oncology · 2017Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
We found that the receptor for erythropoietin (EpoR) is coexpressed with human epidermal growth factor receptor-2 (HER2) in a significant percentage of human breast tumor specimens and breast cancer cell lines. Exposure of HER2 and EpoR dual-positive breast cancer cells to recombinant human erythropoietin (rHuEPO) activated cell signaling. Concurrent treatment of the cells with rHuEPO and trastuzumab reduced the cells' response to trastuzumab both in vitro and in vivo. We identified Jak2-mediated activation of Src and inactivation of PTEN as underlying mechanisms through which rHuEPO antagonizes trastuzumab-induced therapeutic effects. Furthermore, we found that compared with administration of trastuzumab alone, concurrent administration of rHuEPO and trastuzumab correlated with shorter progression-free and overall survival in patients with HER2-positive metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.